Kymera Therapeutics, Inc. is focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. The Company’s proprietary targeted protein degradation platform, Pegasus, utilizes the body’s natural E3 ligase-directed protein disposal system called the ubiquitin-proteasome system (UPS) to target and degrade disease-causing proteins. The Company’s IRAK4, IRAKIMiD, and STAT3 programs exemplify the Company’s focus on addressing high impact targets that have been elusive to conventional modalities and that drive the pathogenesis of multiple serious diseases with significant unmet medical needs. The Company is initially developing molecules in its IRAK4 program for the treatment of a broad set of immune-inflammatory diseases including its first indication of focus, hidradenitis suppurativa (HS). The Company is also developing its IRAKIMiD program for the treatment of MYD88 mutant B-cell lymphomas. Additionally, the Company is developing its STAT3 program for the treatment of hematologic malignancies, solid tumors and autoimmune diseases.